SuperworthLantern Pharma LTRN
- Market cap
- $8.1M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- not a meaningful number
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- not a meaningful number
- Net margin
- n/m
- not a meaningful number
- Free cash flow yield
- n/m
- not a meaningful number
Lantern Pharma's trailing earnings are negative, so it has no PE.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $2.2M+215% | $3.6M+59% | $4.3M+67% | $3.9M+9% | $3.7M+68% | $4.3M+20% | $3.3M−23% | $3.1M−21% | $2.4M−34% | $2.7M−36% | $1.7M−47% | $1.8M−42% |
| SG&A | $1.3M−9% | $1.3M−17% | $1.5M−15% | $1.5M−7% | $1.5M+11% | $1.6M+25% | $1.5M+2% | $1.6M+4% | $1.9M+31% | $1.5M−10% | $1.7M+11% | $1.7M+8% |
| −$3.5M+64% | −$4.9M+28% | −$5.7M+34% | −$5.4M+4% | −$5.2M+47% | −$5.9M+21% | −$4.8M−17% | −$4.7M−14% | −$4.3M−16% | −$4.2M−29% | −$3.4M−29% | −$3.5M−25% | |
| Net income | −$3.2M+40% | −$4.2M+24% | −$5.4M+41% | −$5M+5% | −$4.5M+43% | −$5.9M+40% | −$4.5M−17% | −$4.3M−13% | −$4.2M−7% | −$4.1M−31% | −$3.3M−27% | −$7.1M+63% |
| −$0.29+38% | −$0.39+26% | −$0.51+42% | −$0.46+5% | −$0.42+45% | −$0.54+39% | −$0.42−18% | −$0.40−13% | −$0.39−7% | −$0.36−33% | −$0.30−29% | −$0.57+43% | |
| 10.9M+0% | 10.8M−1% | 10.7M−1% | 10.8M−1% | 10.8M−1% | 10.8M−0% | 10.8M+0% | 10.8M+0% | 10.8M+1% | 11.2M+4% | 11.3M+4% | 12.4M+15% |
SG&A: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY19 and Q1 FY20: 6 months less the 3 months printed beside them.
EPS, diluted: 9 periods, Q1 FY19 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY19 and Q1 FY20: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY19 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Lantern Pharma's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LTRNLantern Pharma | $8.1M | n/m | n/a | n/m | n/m | n/m | |
| ATNMActinium Pharmaceuticals | $47.8M | 4.2× | 3.1× | n/m | n/m | n/m | |
| SPROSpero Therapeutics | $64.6M | 10.1× | 9.5× | 1.4× | −3% | 15.7% | |
| LFVNLifevantage | $73.4M | 14.7× | 19.6× | 0.4× | −20% | 2.8% | |
| Peer median | $64.6M | 10.1× | 9.5× | 0.9× | −12% | 9.2% |
More on Lantern Pharma
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .